Oral anti vascular endothelial growth factors therapeutic agents have been evolving rapidly over the last past decades and became one of the great contributors to advancement of cancer therapy and increasing survival rate of the treated patients.Sorafenib is FDA approved medications for the treatment of solid tumors.In this article, we reported the clinical features of the first Saudi patient presenting with corneo-uveal retinal adverse effects with subsequent bilateral irreversible blindness.
Sunitinib and Ponatinib are two biological drugs that have greatly contributed to the treatment advances of different types of cancer. However, the ocular adverse effects of those drugs were not well studied and only a few case reports, within the literature, described patients who developed vision loss and ocular changes. In this study, we reported the clinical presentation of the first two Saudi patients presenting with a sudden loss of vision due to recent lines of treatment. The effect of these drugs has strongly implied the importance of cautious use and the need for further studies on their ocular side effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.